Facebook Instagram Linkedin Twitter Website
Home Blog Page 9

Creatine isn’t just for the gym: a retail rethink for brains, sleep, skin, rehab, and metabolic health

By
IHR Magazine
-
0

Creatine has lived too long on the sport-nutrition shelf. A growing body of science shows it touches far more than muscle—supporting cognition under sleep loss, serving as an adjunct in mood research, pairing with exercise for metabolic health, appearing in topical skin care, and showing potential in rehabilitation settings. That adds up to a bigger basket, new customers, and smarter merchandising for retailers.

The quick science: why creatine belongs in multiple aisles

Creatine helps recycle ATP—the cell’s fast energy currency—via the phosphocreatine system in both muscle and brain. When tissues are energy-stressed (intense effort, sleep deprivation, recovery, illness), higher phosphocreatine availability can help maintain performance. That mechanism explains why the most interesting findings now sit beyond sport.

Sleep loss rescue (acute use)

Randomized trials have shown that a single high dose of creatine taken during prolonged sleep deprivation can improve processing speed and certain cognitive measures for several hours. This is not a replacement for sleep, but it gives you a credible education story for shift workers, new parents, students, and travellers when framed responsibly.

Brain and mood (investigational)

Creatine is under investigation as an adjunct in persistent post-concussive symptoms and major depression (with positive signals, including in women when combined with SSRIs). These are clinical contexts—appropriate for professional education and pharmacist consultations—not for front-of-label consumer claims.

Pregnancy frontier (strictly experimental)

Preclinical models suggest maternal creatine may help protect the fetus from hypoxic injury and reduce post-hypoxia seizure burden, with additional signals around fetal lung protection in infection models. Human studies are underway, but this is not established care. Retail guidance: avoid consumer claims; advise pregnant customers to consult their care team.

Skin care: topical creatine

Topical creatine can penetrate skin and has been studied for supporting collagen synthesis and reducing signs of photoageing. This sits squarely in the dermocosmetics aisle: use in-store education to distinguish topical cosmetic benefits from oral supplementation.

Metabolic health—with exercise

In adults with type 2 diabetes, creatine combined with an exercise programme has improved glycaemic control in controlled trials, likely via increased GLUT-4 translocation. The retail message is straightforward: pair creatine education with resistance bands, walking programmes, or in-store fitness workshops.

Rehab and respiratory (mixed but promising)

Pulmonary rehabilitation studies show mixed results; some trials report functional gains and improved exercise performance (including in combinations like CoQ10 + creatine), while others show no additive benefit. Expect variability, set expectations, and position creatine as a potential adjunct within clinician-directed programmes. In musculoskeletal rehab and periods of immobilisation, creatine may aid recovery phases but does not reliably prevent short-term disuse atrophy.

Bigger wins for plant-based customers

Vegetarians and vegans tend to have lower baseline creatine stores and can see larger responses in muscle performance and some cognition measures. This is an easy, evidence-aligned talking point in your plant-based section.

What to stock—and how to explain it

Choose creatine monohydrate. It’s the research standard. Micronised powder mixes more easily; capsules help adherence; gummies trend but often under-dose.

Dosing made simple

  • Daily steady approach: 3–5 g per day, no loading. Reaches saturation in ~3–4 weeks with fewer GI complaints.
  • Loading option (for speed): ~20 g per day split into 4 doses for 5–7 days, then 3–5 g per day.

Quality signals for shelf tags

  • Third-party testing (e.g., NSF Certified for Sport, Informed Choice) for label accuracy and contaminant screening.
  • Transparent sourcing (e.g., Creapure®) as a purity story many educated consumers recognise.

Safety, myths, and Canadian compliance

  • Renal function: In healthy users, modern reviews and position papers do not show harm to kidney function with recommended use. Serum creatinine can rise due to creatine turnover, which may confound lab results—flag this in pharmacist training.
  • Hydration and GI: Encourage daily hydration; start low if sensitive.
  • Regulatory: Align your marketing with Health Canada’s creatine monograph and permitted performance claims. Avoid disease claims in consumer-facing materials. Ensure appropriate NPNs on products. If you carry supplemented foods with added creatine, ensure labelling compliance under current rules.

Merchandising plays that work

1) Cognition & shift-work end-cap: Creatine monohydrate beside magnesium glycinate, L-theanine, and a caffeine-free electrolyte mix. Message: “Support focus after a short night.”

2) Active-ageing bay: Place creatine with protein powders, collagen, and resistance bands. Use a simple card: “Start with 3–5 g daily.”

3) Plant-based performance shelf: Vegan-certified creatine with B12 and iron education. Message: “Plant-based? You may benefit more.”

4) Pharmacy consult point: Train pharmacists to recognise scenarios where creatine discussion is appropriate (sleep-deprived shift workers; adults starting exercise for glycaemic control; rehab patients already cleared by clinicians).

Staff one-liners

  • “Creatine is daily nutrition for fast energy recycling in muscle and brain.”
  • “If powders are a barrier, offer capsules; if budget matters, bulk monohydrate is best value.”
  • “Expect results to build—consistency beats megadoses.”
  • “Plant-based customers often respond more.”

References

  1. Persky AM, Rawson ES. Safety of creatine supplementation. Sub-cellular Biochemistry.
  2. Kreider RB et al. International society position stand: safety and efficacy of creatine. Journal of the International Society of Sports Nutrition.
  3. McMorris T et al.; Scientific Reports (2024). Creatine supplementation and sleep deprivation—cognitive outcomes.
  4. Lyoo IK et al. Creatine augmentation of SSRIs in women with major depressive disorder. American Journal of Psychiatry.
  5. Sakellaris G et al. Creatine in traumatic brain injury and post-concussive symptoms. Journal of Head Trauma Rehabilitation.
  6. Ellery SJ et al. Maternal creatine for fetal protection—preclinical evidence and early human work. Placenta; Clinical and Experimental Pharmacology & Physiology.
  7. Schmid D et al. Topical creatine and dermal anti-ageing effects. Journal of Cosmetic Dermatology; Beiersdorf research reports.
  8. Gualano B et al. Creatine with exercise improves glycaemic control in type 2 diabetes. Medicine & Science in Sports & Exercise.
  9. Fuld JP et al.; Deacon SJ et al. Creatine (±CoQ10) in COPD rehabilitation—functional outcomes. Thorax; European Respiratory Journal.
  10. Rae C et al.; Benton D & Donohoe R. Vegetarian status, brain creatine, and performance. Proceedings of the Royal Society B; Psychopharmacology.

Paul Stamets brings Turkey Tail and Agarikon to the UN

By
IHR Magazine
-
0

At United Nations Headquarters in New York, internationally renowned mycologist Paul Stamets delivered a message that felt equal parts science briefing and planetary call to action. Framing mushrooms as “stalwart allies” for human and environmental health, he spotlighted two species—Turkey Tail (Trametes versicolor) and Agarikon (Laricifomes officinalis)—and the compelling case for their immune-supporting potential.

For half a century, Stamets has argued that fungi are not fringe; they’re foundational. His appearance at the UN was a marker of how far the field has come—and how far it may go. Turkey Tail and Agarikon, long studied for their bioactive compounds, took centre stage as Stamets outlined how their mycelium—the vast, root-like network beneath the forest floor—may help modulate immune function while advancing soil health, biodiversity, and habitat resilience.

“Speaking at the United Nations was truly an honour,” Stamets said, noting that the chance to present in front of a global audience underscored both the maturing science and the urgency of ecological stewardship. “The immense potential of Agarikon and Turkey Tail mushroom mycelium to support immune function cannot be understated… a true testament to fungi’s inextricable role in the health of both people and planet.”

Beyond the podium, Stamets’ track record is unusually hands-on. As Founder, Member, and Owner of Fungi Perfecti, makers of Host Defence Mushrooms, he has directed the company to reinvest roughly $1 million annually into research—funding clinical trials, building strain libraries, and publishing in peer-reviewed journals. One flagship effort: cultivating what is described as the world’s largest Agarikon culture library to help conserve this at-risk, old-growth species and secure its genetic diversity for future study.

For natural-health retailers, formulators, and clinicians, the implications are immediate. Immune health remains a top-performing category, and consumer interest is shifting from hype to rigour. The conversation is no longer simply “mushrooms are good,” but “which species, which preparation, and what evidence supports the claim?” Mycelium-forward formulas, fruiting-body extracts, substrate transparency, and third-party testing are becoming table stakes. Education matters: positioning these fungi as immune modulators—systems that help the body maintain balance—resonates with today’s informed shopper.

Stamets’ UN moment also landed in a changing ecological narrative. Protecting old-growth habitats, banking endangered strains, and supporting research that links human wellness to biodiversity are no longer niche pursuits; they’re the backbone of a responsible wellness economy. By tying immune support to conservation, the presentation connected two urgent mandates: help people feel better now, and ensure the ecosystems that sustain us can thrive long term.

As the sector professionalizes, expect a sharper focus on clinical endpoints, standardized inputs, and reproducible results. If the UN stage is any indication, mushrooms have graduated from supplement aisle curiosity to serious science—with Turkey Tail and Agarikon leading a movement that blends wellness, conservation, and innovation.

Editor’s note: Mushroom supplements support general health and are not intended to diagnose, treat, cure, or prevent disease. Readers should consult a health-care professional for individual advice.

AI Will Run 90% of Retail Orders by 2028: What It Means for Canada’s Health & Wellness Stores

By
IHR Magazine
-
0

IDC forecasts that by 2028, AI will autonomously manage 90% of the order lifecycle for 45% of retailers. For Canadian health and supplement retailers, that shift will rapidly reshape inventory, fulfilment, loyalty, fraud prevention, and margins.

Why this matters now

The order lifecycle is becoming near-autonomous—from demand sensing to returns. Agentic AI is moving out of pilots and into core retail systems, coordinating people, data, and suppliers with minimal human oversight. For IHR’s audience—natural health, supplement, and wellness retailers—this maps directly to high-mix SKUs, expiry dates, recalls, and loyalty dynamics unique to the category.

What “AI managing the order lifecycle” actually covers.

In practice, AI will forecast and plan by blending promotions, weather, and social signals while flagging at-risk SKUs nearing expiry. It will source and replenish through automated purchase orders tied to vendor SLAs and lot tracking, with substitution logic for compliant alternates. During transaction and fulfilment, it will route orders intelligently to store, DC, or drop-ship and orchestrate curbside or delivery. Post-purchase, agentic service will handle status, exchanges, and serialized returns with robust fraud controls. Loyalty and personalization will tune offers to health goals, preferences, and basket history while respecting Canadian privacy requirements.

Five transformations you’ll feel first

1) Agentic OMS becomes your backbone

Expect autonomous orchestration across split shipments, back-order logic, and store-fulfillment pick paths executed by AI. Near-term win: pilot AI-routed BOPIS and local delivery on your top 200 SKUs, then track cycle time, pick accuracy, and cancellations to establish the baseline.

2) Fraud and deepfake defence becomes mandatory

Returns abuse, synthetic identities, and manipulated media are rising, and AI detection for voice, image, and receipts will become table stakes. Near-term win: introduce image and receipt forensics on returns and step-up verification for high-risk customer-service calls to reduce leakage without adding friction.

3) Computer vision cuts shrink and out-of-stocks

Continuous shelf monitoring improves planogram compliance, exposes phantom stock, and accelerates restocks—vital in wellness where pack sizes, variants, and expiries multiply complexity. Near-term win: activate vision on one high-velocity gondola, such as probiotics, and compare manual versus vision-driven restock latency and waste.

4) AI agents grow a bigger share of e-commerce

Buying assistants on product pages and at checkout will influence a larger portion of online sales, lifting attach rates on bundles like sleep, immunity, and gut health. Near-term win: launch an assistant in top categories to recommend compliant bundles and measure gains in average order value and add-on units.

5) Data platforms become growth engines

Retailers that clean up product and customer data unlock agentic use-cases and monetization, including supplier portals with real-time sell-through and compliance dashboards. Near-term win: stand up a basic PIM plus CDP, and define golden attributes for allergens, dosage forms, and DIN/NPN status to support accurate recommendations.

A 90-day roadmap for Canadian wellness retailers

Days 0–30 focus on foundations: map the order lifecycle end-to-end, tag the slowest steps, consolidate a single inventory truth across store, DC, and e-commerce, and pick two agentic use-cases such as BOPIS routing and returns triage. Days 31–60 are for pilots: deploy an AI assistant for order status and exchanges integrated with OMS/WMS, apply shelf vision to one top category to reduce outs and waste, and enable anomaly scoring for returns and refunds. Days 61–90 emphasize scale and governance: write guardrails for PIPEDA-compliant data retention, model risk, and human-in-the-loop; expand the assistant to bundle recommendations with A/B tests that emphasize Canadian compliance and NPN credentials; and publish weekly reports on fill rate, cycle time, return abuse, and incremental gross margin.

KPIs to watch

Aim to cut order cycle time by 25 to 40 percent through agentic routing, raise fill rate by three to six points through smarter allocation, reduce shrink and out-of-stocks by 20 to 40 percent on vision-enabled shelves, curb return fraud measurably with image and receipt forensics, and track AI-influenced revenue by tagging sessions touched by assistants.

Risks, rules, and the Canadian context

Design for privacy and consent under PIPEDA, minimizing personal data while maximizing first-party context. Keep humans in the loop for health-adjacent claims and any clinical-style recommendations. Guard against model drift by retraining to capture seasonality patterns, such as cold-and-flu or allergy spikes. Refresh store SOPs so staff rely on AI routing where appropriate rather than overriding it by habit.

FAQ

What is “agentic commerce”?
Agentic commerce uses AI agents that can perceive, decide, and act to manage tasks like order routing, returns, and recommendations while coordinating with people when needed.

Is this just for big box stores?
No. Cloud-based OMS, computer vision, and AI assistants are modular and affordable. Start with one shelf, one workflow, or one channel and scale from there.

Will AI replace staff?
Autonomy targets routine work so people can focus on exceptions, premium service, and brand-building interactions that differentiate your store.

How soon will shoppers notice?
Improvements are visible quickly: faster fulfilment, fewer outs, smarter bundles, clearer post-purchase updates, and fewer frustrating exceptions at the counter.

Menopause Relief Without Hormones: What the Evidence Says About Pycnogenol®

By
IHR Magazine
-
0

Part 1 — Pycnogenol® & Menopause Series

Why non-hormonal support matters now
By 2025, more than one billion women will be in menopause or transitioning toward it, most between ages 45–55, with symptoms that can persist for years [1–3]. Vasomotor symptoms—hot flashes and spontaneous sweats—affect up to 80% of perimenopausal women and commonly disturb sleep and mood, with downstream impacts on fatigue, memory and productivity [3–6]. While menopausal hormone therapy can be effective, it carries risks (e.g., venous thromboembolism, stroke, and breast cancer) that prompt many women to seek non-hormonal options [7].

What is Pycnogenol®?
Pycnogenol® is a standardized extract of French maritime pine bark with antioxidant and anti-inflammatory activity. It has been studied across multiple health areas relevant to menopause without affecting sex-hormone levels [8–10].

Clinical signal: symptom relief without altering hormones

  • In a 6-month randomized, double-blind, placebo-controlled trial in 155 peri-menopausal women, Pycnogenol® significantly improved all domains of the Women’s Health Questionnaire (WHQ)—including vasomotor, sleep, mood, cognition, attractiveness and sexual behaviour—versus placebo [10].
  • In a study of 70 women, 100 mg/day for 8 weeks significantly improved 33 common menopausal complaints (hot flashes, night sweats, mood swings, libido, vaginal dryness) versus controls [11].
  • A 3-month RCT (n=170) using 60 mg/day reduced the total menopause symptom score by 17% versus placebo. Importantly, measured sex-hormone levels did not change from baseline or versus placebo, supporting non-hormonal action [9].
  • Another 8-week study reported improvements in vasomotor symptoms, vaginal health, cognition and sleep versus baseline and control [12].
  • A 90-day comparative study in 90 postmenopausal women found greater improvements in psychological, vasomotor and sexual symptoms with Pycnogenol® than with two other botanicals commonly used for menopause [13].

How it may work
Pycnogenol® supports antioxidant balance and inflammatory signalling, areas thought to modulate vasomotor symptoms and overall well-being during the transition [8–10].

Practical notes for retailers and clinicians

  • Research ranges: 60–100 mg/day for 8–24 weeks are commonly studied doses [9–12].
  • Positioning: For women seeking non-hormonal, evidence-based symptom support, including those not candidates for or declining hormone therapy.
  • Counsel: Pair with sleep hygiene, balanced nutrition and physical activity for multi-modal support.

This article is for educational purposes only and is not a substitute for individual medical advice.
References: 1–13 as cited in source list.

 

References:
1. United Nations, Department of Economic and Social Affairs Population Division ,World
Population Prospects 2022 2023 [Available from:
https://population.un.org/wpp/Download/Standard/Population/.
2. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas.
1992;14(2):103-15.
3. Nappi RE, Siddiqui E, Todorova L, Rea C, Gemmen E, Schultz NM. Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey.
Maturitas. 2023;167:66-74.
4. Wu JM, Zelinski MB, Ingram DK, Ottinger MA. Ovarian Aging and Menopause: Current
Theories, Hypotheses, and Research Models. Experimental Biology and Medicine. 2005;230(11):818-28.
5. Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity,
trajectory, and significance in women's lives. Am J Med. 2005;118 Suppl 12B:14-24.
6. Richters JMA. Menopause in Different Cultures. Journal of Psychosomatic Obstetrics & Gynecology. 1997;18(2):73-80.
7. Beral V, Peto R , Pirie K , Reeves G. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
Lancet. 2019;394(10204):1159-68.
8. Oliff H. American Botanical Council – Scientific and clinical Monograph for Pycnogenol. ABC. 2019:1-46.
9. Kohama T, Negami M. Effect of low-dose French maritime pine bark extract on climacteric syndrome in 170 perimenopausal women: a randomized, double-blind, placebo-controlled trial. J Reprod Med. 2013;58(1-2):39-46.
10. Yang HM, Liao MF, Zhu SY, Liao MN, Rohdewald P. A randomised, double-blind, placebo-
controlled trial on the effect of Pycnogenol on the climacteric syndrome in peri-menopausal women. Acta Obstet Gynecol Scand. 2007;86(8):978-85.
11. Errichi S, Bottari A, Belcaro G, Cesarone MR, Hosoi M, Cornelli U, et al. Supplementation with Pycnogenol® improves signs and symptoms of menopausal transition. Panminerva Med. 2011;53(3 Suppl 1):65-70.
12. Luzzi R, Belcaro G, Hosoi M, Feragalli B, Cornelli U, Dugall M, et al. Normalization of
cardiovascular risk factors in peri-menopausal women with Pycnogenol(R). Minerva Ginecol.
2017;69(1):29-34.
13. Cesarone MR, Belcaro G, Cornelli U, Hosoi M, Scipione V, Scipione C, et al. Effects of
Pycnogenol® in women with postmenopausal symptoms: a 90-day comparative study. Panminerva Med. 2023.
14. Hildreth KL, Ozemek C, Kohrt WM, Blatchford PJ, Moreau KL. Vascular dysfunction across the stages of the menopausal transition is associated with menopausal symptoms and quality of life. Menopause. 2018;25(9):1011-9.
15. Moreau KL, Hildreth KL. Vascular Aging across the Menopause Transition in Healthy Women. Adv Vasc Med. 2014;2014.
16. Enseleit F, Sudano I, Periat D, Winnik S, Wolfrum M, Flammer AJ, et al. Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. Eur Heart J. 2012;33(13):1589-97.
17. Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci. 2004;74(7):855-62.
18. Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in
subjects with type 2 diabetes by Pycnogenol supplementation. Nutr Res. 2008;28(5):315-20.
19. Fitzpatrick DF, Bing B, Rohdewald P. Endothelium-dependent vascular effects of Pycnogenol.
J Cardiovasc Pharmacol. 1998;32(4):509-15.
20. Nishioka K, Hidaka T, Nakamura S, Umemura T, Jitsuiki D, Soga J, et al. Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertens Res. 2007;30(9):775-80.
21. Conde DM, Verdade RC, Valadares ALR, Mella LFB, Pedro AO, Costa-Paiva L. Menopause and cognitive impairment: A narrative review of current knowledge. World J Psychiatry. 2021;11(8):412-28.
22. Hosoi M, Belcaro G, Saggino A, Luzzi R, Dugall M, Feragalli B. Pycnogenol(R) supplementation
in minimal cognitive dysfunction. J Neurosurg Sci. 2018;62(3):279-84.
23. Cesarone MR, Belcaro G, Hosoi M, Ledda A, Feragalli B, Maione C, et al. Supplementary
management with Pycnogenol® in Parkinson's disease to prevent cognitive impairment. J Neurosurg Sci. 2020;64(3):258-62.
24. Belcaro G DM, Ippolito E, Hu S, Saggino A, Feragalli B Improvement in cognitive function, attention, mental performance with Pycnogenol® in healthy subjects (55-70) with high oxidative stress. J Neurosurg Sci 2015;59:437-46.
25. Ryan J, Croft, K., Wesnes, K and Stough, C. An examination of the effects of the antioxidant Pycnogenol® on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. J Psychopharmacol. 2008;22(5):553-62.
26. Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin North Am. 2013;39(1):1-19.
27. Jessberger S, Högger P, Genest F, Salter DM, Seefried L. Cellular pharmacodynamic effects of Pycnogenol(R) in patients with severe osteoarthritis: a randomized controlled pilot study. BMC Complement Altern Med. 2017;17(1):537.
28. Canali R, Comitato R, Schonlau F, Virgili F. The anti-inflammatory pharmacology of
Pycnogenol in humans involves COX-2 and 5-LOX mRNA expression in leukocytes. Int
Immunopharmacol. 2009;9(10):1145-9.
29. Grimm T, Chovanova Z, Muchova J, Sumegova K, Liptakova A, Durackova Z, et al. Inhibition of NF-kappaB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflamm (Lond). 2006;3:1.
30. Grimm T, Schäfer A, Högger P. Antioxidant activity and inhibition of matrix
metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). Free Radic Biol Med. 2004;36(6):811-22.
31. Schäfer A, Chovanova Z, Muchova J, Sumegova K, Liptakova A, Durackova Z, et al. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother. 2005;60(1):5-9.
32. Belcaro G, Cesarone MR, Errichi S, Zulli C, Errichi BM, Vinciguerra G, et al. Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol. Redox Rep. 2008;13(6):271-6.
33. Farid R, Mirfeizi Z, Mirheidari M, Rezaieyazdi Z, Mansouri H, Esmaelli H, et al. Pycnogenol supplementation reduces pain and stiffness and improves physical function in adults with knee osteoarthritis. Nutrition Research. 2007;27(11):692-7.
34. Cisar P, Jany R, Waczulikova I, Sumegova K, Muchova J, Vojtassak J, et al. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytother Res. 2008;22(8):1087-92.
35. Belcaro G, Cesarone MR, Errichi S, Zulli C, Errichi BM, Vinciguerra G, et al. Treatment of
osteoarthritis with Pycnogenol. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs,
symptoms, physical performance and vascular aspects. Phytother Res. 2008;22(4):518-23.
36. Mülek M, Seefried L, Genest F, Högger P. Distribution of Constituents and Metabolites of
Maritime Pine Bark Extract (Pycnogenol((R))) into Serum, Blood Cells, and Synovial Fluid of Patients with Severe Osteoarthritis: A Randomized Controlled Trial. Nutrients. 2017;9(5).
37. Zhao H, Wu J, Wang N, Grether-Beck S, Krutmann J, Wei L. Oral Pycnogenol(R) Intake Benefits the Skin in Urban Chinese Outdoor Workers: A Randomized, Placebo-Controlled, Double-Blind, and Crossover Intervention Study. Skin Pharmacol Physiol. 2021:1-11.
38. Marini A, Grether-Beck S, Jaenicke T, Weber M, Burki C, Formann P, et al. Pycnogenol(R) effects on skin elasticity and hydration coincide with increased gene expressions of collagen type I and hyaluronic acid synthase in women. Skin Pharmacol Physiol. 2012;25(2):86-92.
39. Belcaro G, Cesarone MR, Errichi BM, Ledda A, Di Renzo A, Stuard S, et al. Diabetic ulcers: microcirculatory improvement and faster healing with pycnogenol. Clin Appl Thromb Hemost. 2006;12(3):318-23.
40. Ayres EL, Silva JDS, Eberlin S, Facchini G, Vasconcellos C, Costa A. In-vitro effect of pine bark extract on melanin synthesis, tyrosinase activity, production of endothelin-1 and PPAR in cultured melanocytes exposed to Ultraviolet, Infrared, and Visible light radiation. J Cosmet Dermatol. 2021.
41. Grether-Beck S, Marini A, Jaenicke T, Krutmann J. French Maritime Pine Bark Extract
(Pycnogenol(R)) Effects on Human Skin: Clinical and Molecular Evidence. Skin Pharmacol Physiol.2016;29(1):13-7.
42. Pinto CAS, Delfes MFZ, Reis LMd, Garbers LE, Passos PCVdR, Torre DSd. The use of
pycnogenol in the treatment of melasma. Surgical & Cosmetic Dermatology.2015;7(3).
43. Ni Z, Mu Y, Gulati O. Treatment of melasma with Pycnogenol. Phytother Res. 2002;16(6):567-71.
44. Saliou C, Rimbach G, Moini H, McLaughlin L, Hosseini S, Lee J, et al. Solar ultraviolet-induced erythema in human skin and nuclear factor-kappa-B-dependent gene expression in keratinocytes are modulated by a French maritime pine bark extract. Free Radic Biol Med. 2001;30(2):154-60.
45. Kim YJ, Kang KS, Yokozawa T. The anti-melanogenic effect of pycnogenol by its anti-oxidative actions. Food Chem Toxicol. 2008;46(7):2466-71.
46. Kwon SH, Na JI, Choi JY, Park KC. Melasma: Updates and perspectives. Experimental
Dermatology. 2019;28(6):704-8.
47. Zouboulis CC, Blume-Peytavi U, Kosmadaki M, Roó E, Vexiau-Robert D, Kerob D, et al. Skin, hair and beyond: the impact of menopause. Climacteric. 2022;25(5):434-42.
48. Chaikittisilpa S, Rattanasirisin N, Panchaprateep R, Orprayoon N, Phutrakul P, Suwan A, et al. Prevalence of female pattern hair loss in postmenopausal women: a cross-sectional study. Menopause. 2022;29(4):415-20.
49. Cai C, Zeng B, Lin L, Zheng M, Burki C, Grether‐Beck S, et al. An oral French maritime pine bark extract improves hair density in menopausal women: A randomized, placebo‐controlled, double blind intervention study. Health Science Reports. 2023;6(1).
50. Cesarone MR, Belcaro G, Agus GB, Ippolito E, Dugall M, Hosoi M, et al. Chronic venous
insufficiency and venous microangiopathy: management with compression and Pycnogenol(R). Minerva Cardioangiol. 2019;67(4):280-7.
51. Steigerwalt R, Belcaro G, Cesarone MR, Di Renzo A, Grossi MG, Ricci A, et al. Pycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy. J Ocul Pharmacol Ther. 2009;25(6):537-40.
52. Wang S, Tan D, Zhao Y, Gao G, Gao X, Hu L. The effect of Pycnogenol® on the
microcirculation, platelet function and ischaemic myocardium in patients with coronary artery diseases. European Bulletin of Drug Research. 1999;7(2):19-25.
53. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G, et al.
Improvement of diabetic microangiopathy with pycnogenol: A prospective, controlled study.
Angiology. 2006;57(4):431-6.
54. Luzzi R BG, Hu S, Dugall M, Hosoi M, Cacchio M, Ippolito E, Corsi M Improvement in
symptoms and cochlear flow with Pycnogenol in patients with Meniere’s disease and tinnitus. Minerva Med 2014;105:245-54.
55. Grossi MG, Belcaro G., Cesarone, M.R., Duggall, M., Hosoi, M Cacchio,. Improvement in
cochlear flow with Pycnogenol® in patients with tinnitus: a pilot evaluation. Panminerva Med. 2010;52(2):63-7.
56. Chovanova Z, Muchova J, Sivonova M, Dvorakova M, Zitnanova I, Waczulikova I, et al. Effect of polyphenolic extract, Pycnogenol, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder. Free Radic Res. 2006;40(9):1003-10.
57. D̆uračková Z, Trebatický B, Novotný V, Žitňanová I, Breza J. Lipid metabolism and erectile function improvement by pycnogenol®, extract from the bark of pinus pinaster in patients suffering from erectile dysfunction-a pilot study. Nutrition Research. 2003;23(9):1189-98.
58. Devaraj S V-LS, Kaul N, Schönlau F, Rohdewald P, Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters plasma lipoprotein profile. Lipids. 2002;37(10):931-4.
59. Kolacek M, Muchova J, Dvorakova M, Paduchova Z, Zitnanova I, Cierna I, et al. Effect of
natural polyphenols (Pycnogenol) on oxidative stress markers in children suffering from Crohn's disease–a pilot study. Free Radic Res. 2013;47(8):624-34.
60. Errichi S, Bottari, A., Belcaro, G., Cesarone, M.R., Hosoi, M., Cornelli, U., Dugall, M., Ledda, A., Feragalli, B. Supplementation with Pycnogenol® improves signs and symptoms of menopausal transition. Panminerva Med. 2011;53(3):65-70.
61. Al-Badr A, Al-Shaikh G. Recurrent Urinary Tract Infections Management in Women: A review. Sultan Qaboos Univ Med J. 2013;13(3):359-67.
62. Lüthje P, Brauner H, Ramos NL, Ovregaard A, Gläser R, Hirschberg AL, et al. Estrogen supports urothelial defense mechanisms. Sci Transl Med. 2013;5(190):190ra80.
63. Cotellese R, Hu S, Cesarone MR, Belcaro G, Dugall M, Feragalli B, et al. Pycnogenol®
supplementation prevents inflammation and symptoms in recurrent, non-severe urinary infections. Panminerva Med. 2021;63(3):343-8.
64. Ledda A, Hu S, Cesarone MR, Belcaro G, Dugall M, Feragalli B, et al. Pycnogenol®
Supplementation Prevents Recurrent Urinary Tract Infections/Inflammation and Interstitial Cystitis. Evidence-Based Complementary and Alternative Medicine. 2021;2021:9976299.

NaturVet’s Lickable Supplements Make Cat Wellness Simple: Calming, Multi-Vitamin, and Hip & Joint

By
IHR Magazine
-
0

NaturVet’s Lickable Supplements Make Cat Wellness Simple

Cats can be particular about pills and powders. NaturVet, a leader in pet health and wellness innovation, has introduced a solution designed for real-world compliance: Lickable Supplements for cats. Available in Calming, Multi-Vitamin, and Hip & Joint, each (3 oz/89 mL) pump-dispensed formula supports common feline health needs in a convenient, mess-free format.

“Keeping your cat healthy has never been easier,” said Geoff Granger, CEO at NaturVet. “With a variety of formulas available, pet parents can choose targeted support without the struggle.”

Formulated by veterinarians and focused on simplicity and effectiveness, the line features proven actives commonly used in feline care, including glucosamine, MSM, hyaluronic acid, chamomile, melatonin, taurine, and hemp seed. The pump ensures easy delivery and consistent dosing—dispense into a dish or onto a lick mat and let the cat do the rest.

What’s in the Line

  • Calming: Tailored with melatonin, chamomile, and hemp seed to help ease tension during stressors such as travel, grooming, thunderstorms, or fireworks.
  • Multi-Vitamin: A daily foundation with essential vitamins and minerals that may be lacking in typical diets to support overall health and immunity.
  • Hip & Joint: Features glucosamine, MSM, and hyaluronic acid to help maintain healthy connective tissue and support hip and joint function—important for active and ageing cats alike.

Why It Matters for Retailers

  • Compliance-first format: Palatable, lickable texture increases acceptance and repeat purchase.
  • Clear need states: Calming, foundational nutrition, and mobility remain top demand drivers in pet supplements.
  • Easy merchandising: Compact bottles, simple dosing instructions, and targeted claims simplify shelf education.

How to Use

Pump the recommended amount (per label directions) into a cat’s dish or onto a lick mat. Use daily for ongoing support, and during specific stress events for Calming.

Consumer Reports flags lead risks in protein powders — MuscleTech® sample reports no detectable lead

By
IHR Magazine
-
0

By IHR Magazine Staff

Consumer Reports has reignited the debate over heavy metals in protein supplements, reporting that more than two-thirds of 23 powders and shakes it tested exceeded its daily “level of concern” for lead (0.5 µg/day). Plant-based products were disproportionately affected.

Against that backdrop, Iovate Health Sciences International Inc. says the MuscleTech® protein powder included in the Consumer Reports investigation registered no detectable lead, based on the laboratory’s method detection limit. The company framed the result as validation of its quality-assurance programme, which includes ingredient sourcing controls, in-house verification, and accredited third-party testing.

Why this matters for Canadian health retailers

Heavy metal headlines create immediate questions at the shelf: Which brands are testing? What standards are they using? And what does “no detectable” actually mean? Consumer Reports’ findings will likely drive customers to ask for proof of testing and clear quality claims. For retailers, that makes supplier transparency—and documentation—non-negotiable.

What Consumer Reports found

  • Scope: 23 powders and ready-to-drink shakes across dairy, beef and plant sources.
  • Key takeaway: Most products exceeded CR’s 0.5 µg/day lead “level of concern”; two specific products were flagged for complete avoidance; others were recommended for limited consumption.
  • Trend: Compared with prior CR work, fewer products now show undetectable lead, and average lead levels appear higher—especially among plant-based options.

CR’s threshold is grounded in California Proposition 65 guidance and is more conservative than some federal perspectives; nonetheless, public-health agencies emphasise that no amount of lead exposure is risk-free.

“Undetectable” reflects a laboratory’s method detection limit—it does not assert absolute zero. Results can vary by batch, serving size, flavour matrix, and analytical method. Still, landing below detection in a high-profile, independent test is a strong quality signal consumers and trade buyers can understand. In this case, Iovate reports that the specific MuscleTech protein powder CR tested fell below the lab’s detection threshold for lead.

Inside Iovate’s quality playbook

Iovate (headquartered in Oakville, Ontario) highlights a multi-layer system: vetted suppliers, in-house verification, and independent lab testing for heavy metals like lead, aligned to recognised guidelines and industry best practices—aimed at protecting product purity from raw material to finished goods.

Retailer checklist: turning scrutiny into trust

  1. Request Certificates of Analysis (COAs) per lot for heavy metals, including lead, cadmium, arsenic, and mercury.
  2. Confirm testing methods and limits (e.g., ICP-MS) and whether results are expressed per serving and per daily use.
  3. Ask about vendor controls: supplier qualification, ingredient traceability, and ongoing verification frequency.
  4. Mind the claims environment: if products make broader health claims, ensure Canadian compliance (e.g., labelling, permissible claims) and keep documentation on file.
  5. Educate staff: align talking points so your team can address consumer questions confidently—especially on “undetectable” versus “safe.”

The bottom line

With Consumer Reports placing protein powders under a magnifying glass, documented quality has become a frontline differentiator. For retailers, brands that can show their work—with third-party results and clear QA processes—will earn the benefit of the doubt. Iovate’s MuscleTech outcome in the CR testing provides one such proof point for buyers evaluating shelf space.

Pycnogenol® for Menopause: Evidence-Based, Hormone-Free Relief

By
IHR Magazine
-
0

As per WHO, more than 1 billion women will experience menopause by 2025. Menopause transition is a life-changing phase that occurs between 45 and 55 years and can last from a few months up to 10 years (1, 2).

Menopause transition not only marks the end of fertile years, but it can also affect the whole body because of hormonal fluctuations. Vasomotor symptoms, specifically hot flashes and spontaneous sweats are considered the most frequent and most bothersome symptoms during menopause, affecting up to 80% of perimenopausal women (3). Hot flashes and spontaneous sweats during menopause transition can lead to sleep disruption and depressed mood – two other common symptoms of menopause transition. This results in fatigue, irritability, forgetfulness and decreased work productivity, all frequently described by perimenopausal women (3).

Other typical climacteric issues include an increased risk of cardiovascular problems, cognitive impairments, sexual dysfunction (vaginal dryness, loss of libido, dyspareunia), joint and muscle aches, hair and skin problems and impaired sense of attractiveness (4, 5). Interestingly, women from different cultures perceive the severity and mere occurrence of various symptoms very differently (6).

Hormone therapy (especially estrogen-progestogen preparations) has for a long time been a common way to treat menopausal symptoms. However, this treatment may cause an increased risk of severe adverse effects, including venous thromboembolism, strokes and even breast cancer (7). Thus, many women are looking for non-hormonal and natural ways to cope with the signs and symptoms of menopausal transition.

Pycnogenol®, French maritime pine bark extract is a natural antioxidant and anti-inflammatory food supplement, that was found to have beneficial properties for the various health impairments in perimenopausal women. It has been established that Pycnogenol® does not only improve menopausal symptoms but it also helps with cardiovascular, joint, skin and hair health without affecting hormone levels (8, 9).

Pycnogenol® relieves menopause transition without any impact on hormonal levels

Pycnogenol® relieves menopausal symptoms

Pycnogenol® has demonstrated remarkable efficacy in addressing various conditions and disorders associated with menopause. Numerous studies have been conducted, involving nearly 600 menopausal women, to investigate the effects of Pycnogenol® on climacteric symptoms (9-13), providing substantial evidence of its benefits. A randomized, double-blind placebo-controlled 6-month study with 155 peri-menopausal women found all symptoms of the Women’s Health Questionnaire (WHQ) to be significantly improved in the Pycnogenol® supplementing subjects, as compared to placebo controls (10). The symptoms on the WHQ include somatic (tiredness, headache) and vasomotor problems (hot flashes, sweating), depressed mood, memory and concentration issues, attractiveness, anxiety, sexual behavior, sleep, and menstrual problems.

In another study, the symptoms of 70 women in menopausal transition were evaluated with 38 subjects being supplemented with 100 mg Pycnogenol® per day for 8 weeks (11). The scoring system included 33 common signs and symptoms of menopausal complaints, such as hot flashes, night sweats, mood swings, irregular periods, loss of libido and vaginal dryness, which were improved significantly after Pycnogenol® intake.

A significant efficacy of a low dosage of Pycnogenol® (60 mg daily) on climacteric symptoms could be shown in a randomized, double-blind placebo-controlled investigation with 170 women (9). In this study, the total menopause symptom score of the women was reduced by 17% compared to placebo control after 3 months, along with the improvement of arthritic or muscular pain, fatigue or sleep problems. In this study, blood plasma levels of different sexual hormones were investigated as well. The results showed that after Pycnogenol® intake, none of the hormone levels showed significant changes compared to baseline or placebo, providing further evidence of its safety.

The main symptoms of menopausal transition could be shown to be improved in a study with 70 women, who took Pycnogenol® for 8 weeks (12). Vasomotor symptoms, vaginal problems, cognitive impairment, and sleep disorders were significantly improved compared to baseline scores as well as to the control group.

A very recently published study on menopause compared the effects of Pycnogenol® to two other plant extracts that are commonly used against menopausal symptoms (13). Psychological as well as vasomotor and sexual symptoms were improved more with Pycnogenol® compared to the other tested extracts in the 90 postmenopausal women in the study.

Pycnogenol® maintains a healthy cardiovascular system

The frequency and severity of perimenopausal symptoms is associated with vascular dysfunction (14). This explains the increased risk of menopausal women for cardiovascular diseases (15). One of the vastly researched properties of Pycnogenol® is its positive effect on the vascular and endothelial health (10, 16-18). The suggested mechanism of action of Pycnogenol® is an activation of the endothelial nitric oxide synthase, which leads to an optimized NO generation (19, 20). This results in vasorelaxation and improved tissue perfusion.

Supplementation of peri-menopausal women with 100 mg Pycnogenol® per day for 6 months was shown to normalize high blood pressure and to improve blood lipid profile (12). Cardiovascular risk factors (homocysteine and CRP values) improved significantly, and plasma free radicals decreased significantly by 22%.

Similar beneficial effects on blood pressure and blood lipid profile were shown in another study on menopausal women who took Pycnogenol® for half a year, leading to a significantly reduced risk for cardiovascular diseases (10).

Pycnogenol® benefits mental fitness

Researchers have found a potentially important role of estrogen protecting neurons and ensuring neuronal function (21). This could explain a commonly described subtle cognitive decline during menopause (21). A healthy diet, physical activities, enough sleep and staying mentally active helps maintain a healthy cognitive function.

Several studies have shown that Pycnogenol® contributes to preserving healthy mental performances and to managing mild cognitive impairment (22-25). Attention, mental performance, memory, and daily tasks, like making decisions or coping with daily problems have been shown to be improved after supplementation with Pycnogenol®.

Pycnogenol® improves bone and joint health

Many menopausal women complain about increased joint pain and indeed, there are several hypotheses regarding the decreasing estrogen levels during menopause. As a consequence, osteoarthritis prevalence and severity increases during menopause (26). In studies with Pycnogenol®, it was observed that pro-inflammatory and degradation markers were significantly decreased after supplementation (27-31). Specifically, the metabolites that are produced after Pycnogenol® intake have been shown to prevent the release of inflammation markers and tissue degradation mediators. In addition, Pycnogenol® improved discomfort, stiffness, physical function and reduced the need for analgesic medication in patients presenting with signs of osteoarthritis (32-35). Metabolites of Pycnogenol® could be detected in the fluid around the knee cartilage, which explains the observed beneficial effects (36).

Pycnogenol® supports skin health and beauty

In over 20 published dermatological clinical investigations, Pycnogenol® was shown to provide numerous health benefits to the skin. These benefits include increased skin hydration, improved skin microcirculation, greater skin elasticity and decreased pigmentation, leading to a beautifully glowing skin appearance with less wrinkles (37-45).

A placebo-controlled double-blind study investigated the effects of Pycnogenol® on the skin health of 78 subjects, who work outdoors in a highly polluted urban area. After 3 months, the skin barrier measured as water loss of the skin during the hot summer season was improved by 14% with Pycnogenol® supplementation and was increased by 5% with placebo (37). Thus, Pycnogenol® led to an improvement of skin moisture compared to placebo, which was additionally investigated. Furthermore, skin elasticity was shown to be improved by 13% after supplementation, compared to an increase of 1% in the placebo group.

Interestingly, clinical investigations of Pycnogenol® supplementation for 12 weeks with menopausal women, aged 55 to 68 years revealed increased hyaluronic acid synthase levels within the skin by 44%, leading to improved skin hydration (38). Hyaluronic acid synthase is the natural source of water-binding hyaluronic acid in the dermis, which moisturizes the skin from the inside, keeping it taut and smooth. Consequently, an average skin-hydration increase by 21% in the group of Pycnogenol® supplementation was found, particularly in women presenting with dry skin prior to Pycnogenol® intake. In this study, Pycnogenol® was also shown to improve skin elasticity by 25% and decrease skin fatigue by 30%. The results were paralleled by Pycnogenol®’s ability to generate skin´s connective tissue collagen in average by 40%. These very interesting results explain the efficacy of Pycnogenol® on skin hydration and elasticity.

In addition to stimulating the synthesis of new collagen, Pycnogenol® metabolites inhibit the release and activity of destructive enzymes (metalloproteinases 1,2 and 9), which break down dermal tissue proteins, like collagen or elastin (29, 30). The reduced activity of these lytic enzymes saves the connective tissues from degradation, representing the basis for maintaining an elastic, smooth and youthful looking skin.

To ensure sufficient supply of nutrients and oxygen to all parts of the skin, blood circulation of the micro vessels must be in good functional condition. Pycnogenol® was shown to improve capillary blood flow by 40%, indicating better microcirculation (39).

Melasma – dark spots on the skin – can be caused by UV exposure, by predisposed genetic background but also by female hormone fluctuation during menopause transition (46). Pycnogenol® was shown to reduce over-pigmentation and melasma resulting in a more even, bright looking skin (37, 40-43).

A recently published study investigated the depigmenting action of Pycnogenol® and found that tyrosinase activity was significantly reduced by 66.5% and other pigmentation-related mediators were downregulated in UV-light treated human melanocytes (40). Tyrosinase is an enzyme that activates the production of melanin – the pigments responsible for skin darkening. From their results, they conclude that Pycnogenol® “contribut[es] to the inhibition of pathways associated with skin hyperpigmentation”.

These findings of Pycnogenol®’s ability to counteract skin hyperpigmentation were clinically validated in another study (41). In this clinical trial with 20 women, oral supplementation with Pycnogenol® was shown to significantly lower UV-induced expression of the pigment synthesizing enzymes tyrosinase-related protein 1 by 75% and tyrosinase by 51%, which are both linked to long-lasting pigmentation.

In another clinical study, the oral intake of Pycnogenol® has been observed to reduce the “melasma area and severity index” by 58% in 31 Brazilian women after 90 days (42). Additionally, the “melasma quality of life scale” was significantly improved by 29% and 94.5% of the patients experienced subjective improvement.

In the study on urban outdoor workers, mentioned before, Pycnogenol® improved skin lightening significantly by 13.8% after 12 weeks of supplementation (37). In the placebo group, subjects experienced a slight decrease in skin lighting due to sun radiation and pollution, reflecting a significant increase in skin color. Skin color lightening was assessed on the cheeks of the participants by the individual typology angle (ITA°), which is an objective classification of the skin color in dermatology and cosmetology.

Furthermore, a study with 30 women with melasma reported a fairer skin complexion with 22% lower pigment intensity following four weeks intake of Pycnogenol® (43). Additionally, Pycnogenol® was shown to effectively decrease the area of over-pigmented skin by 38%, leading to smaller spots.

Skin ageing processes are highly accelerated by exposure of skin to UV radiation. In a clinical trial, Pycnogenol® was shown to increase the resistance of participant’s skin to solar UV exposure, needed to trigger skin redness (minimal erythema dose) (44). Different doses of oral Pycnogenol® supplementation to 21 healthy volunteers with fair skin showed significant photo-protective effects, increasing the minimal dose of light needed to produce erythema (skin reddening) dose-dependently by 60% and 85% respectively.

The results of these studies suggest that Pycnogenol® provides potent photo-protective and melasma-reducing effects from inside out, in addition to topical skin protection and shadowing.

Pycnogenol® improves hair quality

Some menopausal women will experience noticeable changes to hair quality and density during menopause. Those menopausal changes may include hair loss, hair thinning, reduced hair growth and density as well as altered hair quality and structure (47). A 2022 study found that more than half of menopausal women experience female pattern hair loss (48).

A recently published double-blind, randomized, placebo‐controlled study reveals a natural, safe and effective path for women who face hair thinning (49). The study was conducted for 6 months with 76 healthy menopausal women between 45 and 60 years. Remarkably, oral intake of Pycnogenol® led to a significant increase of hair density of 30%, compared to baseline and of 15% compared to placebo after 2 months. The effects of Pycnogenol® stayed on a highly improved level after longer supplementation.

In addition, the study showed that Pycnogenol® significantly reduced water loss from the skin of subjects’ scalp, compared to the placebo group. This leads to a better regulated scalp skin moisture balance for healthier hair and scalp.

The study also confirmed that Pycnogenol® intake positively affects microcirculation in the skin, leading to a better supply of nutrients and oxygen to the hair follicle.

According to a questionnaire in a previously published study with peri-menopausal women, Pycnogenol® reduced hair loss complaints by 31% after 8 weeks (11).

There are several mechanisms of action that can explain Pycnogenol®’s efficacy for hair health and beauty. Healthy microcirculation is vital for maintaining good hair quality as it leads to a well-functioning supply of nutrients and oxygen to the scalp and the hair follicles.

In several previously published studies, Pycnogenol® was shown to improve circulation in small blood vessels in the body, like the very fine micro vessels in the skin, fingertips and in the inner ear or the retinal capillaries in the eye (39, 49-55).

In addition, Pycnogenol® protects hair follicles by capturing free radicals, generated either by stress, sun rays, pollution, or inflammation. In many studies, it was shown that Pycnogenol® has potent anti-inflammatory (28, 29, 31) and strong antioxidant activities (10, 16, 25, 56-60).

Pycnogenol® for urinary tract infection symptoms

Women are 8-times more likely to get a urinary tract infection (UTI) (61). (Post-) menopausal women are at an even higher risk, as the lowered levels of estrogen can lead to a decreased production of antimicrobial peptides and proteins in the bladder (62).

Recently, it could be shown that Pycnogenol® intake has beneficial effects on the signs and symptoms and number of recurrent UTIs in women (63, 64). Interestingly, even more so as the traditionally used cranberry extract. Again, this can be explained by the strong anti-inflammatory and antioxidant effects of Pycnogenol®.

Pycnogenol® French maritime pine bark extract is a safe, natural, hormone-free and evidence-based solution to effectively relieve the main menopausal symptoms as well as several health and beauty impairments commonly reported by ageing women.

For more information, please visit www.pycnogenol.com.

Article written by Dr. Franziska Weichmann, Manager of Scientific Communications and Product Development at Horphag Research.

About Pycnogenol

Pycnogenol® is a French maritime pine bark extract studied as a hormone-free option for menopause. Evidence suggests it may reduce hot flashes, support sleep and mood, and benefit skin, hair and cardiovascular health—without changing hormone levels. It’s a complementary approach for women seeking non-hormonal relief.

People Also Ask (FAQ) 

What is Pycnogenol® and how might it help in menopause?

  1. Pycnogenol® is a standardized pine bark extract rich in procyanidins. Studies suggest it can ease vasomotor symptoms (hot flashes, sweats), support sleep and mood, and help skin, hair and cardiovascular markers during menopause—without altering sex-hormone levels.
  2. Is Pycnogenol® hormone-free?
    Yes. Clinical data indicate Pycnogenol® provides symptom relief without significant changes to sex-hormone levels, making it a non-hormonal option for women who can’t—or prefer not to—use hormone therapy.
  3. Which menopause symptoms does Pycnogenol® address?
    Research reports improvements in hot flashes, sleep quality, mood and cognitive performance, plus benefits for skin hydration/elasticity, hair density and select cardiovascular risk markers.
  4. How long until benefits are noticed?
    Timelines vary by outcome and dosage, but trials commonly report changes within 8–12 weeks, with additional benefits over 3–6 months alongside healthy lifestyle habits.
  5. Can Pycnogenol® be taken with other supplements?
    Often, yes, but combinations should be individualised. Readers should consult a qualified health professional, especially if using prescription medicines or managing chronic conditions.

References:

1. United Nations, Department of Economic and Social Affairs Population Division ,World Population Prospects 2022 2023 [Available from: https://population.un.org/wpp/Download/Standard/Population/.

2. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 1992;14(2):103-15.

3. Nappi RE, Siddiqui E, Todorova L, Rea C, Gemmen E, Schultz NM. Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey. Maturitas. 2023;167:66-74.

4. Wu JM, Zelinski MB, Ingram DK, Ottinger MA. Ovarian Aging and Menopause: Current Theories, Hypotheses, and Research Models. Experimental Biology and Medicine. 2005;230(11):818-28.

5. Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women’s lives. Am J Med. 2005;118 Suppl 12B:14-24.

6. Richters JMA. Menopause in Different Cultures. Journal of Psychosomatic Obstetrics & Gynecology. 1997;18(2):73-80.

7. Beral V, Peto R , Pirie K , Reeves G. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159-68.

8. Oliff H. American Botanical Council – Scientific and clinical Monograph for Pycnogenol. ABC. 2019:1-46.

9. Kohama T, Negami M. Effect of low-dose French maritime pine bark extract on climacteric syndrome in 170 perimenopausal women: a randomized, double-blind, placebo-controlled trial. J Reprod Med. 2013;58(1-2):39-46.

10. Yang HM, Liao MF, Zhu SY, Liao MN, Rohdewald P. A randomised, double-blind, placebo-controlled trial on the effect of Pycnogenol on the climacteric syndrome in peri-menopausal women. Acta Obstet Gynecol Scand. 2007;86(8):978-85.

11. Errichi S, Bottari A, Belcaro G, Cesarone MR, Hosoi M, Cornelli U, et al. Supplementation with Pycnogenol® improves signs and symptoms of menopausal transition. Panminerva Med. 2011;53(3 Suppl 1):65-70.

12. Luzzi R, Belcaro G, Hosoi M, Feragalli B, Cornelli U, Dugall M, et al. Normalization of cardiovascular risk factors in peri-menopausal women with Pycnogenol(R). Minerva Ginecol. 2017;69(1):29-34.

13. Cesarone MR, Belcaro G, Cornelli U, Hosoi M, Scipione V, Scipione C, et al. Effects of Pycnogenol® in women with postmenopausal symptoms: a 90-day comparative study. Panminerva Med. 2023.

14. Hildreth KL, Ozemek C, Kohrt WM, Blatchford PJ, Moreau KL. Vascular dysfunction across the stages of the menopausal transition is associated with menopausal symptoms and quality of life. Menopause. 2018;25(9):1011-9.

15. Moreau KL, Hildreth KL. Vascular Aging across the Menopause Transition in Healthy Women. Adv Vasc Med. 2014;2014.

16. Enseleit F, Sudano I, Periat D, Winnik S, Wolfrum M, Flammer AJ, et al. Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. Eur Heart J. 2012;33(13):1589-97.

17. Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci. 2004;74(7):855-62.

18. Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutr Res. 2008;28(5):315-20.

19. Fitzpatrick DF, Bing B, Rohdewald P. Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol. 1998;32(4):509-15.

20. Nishioka K, Hidaka T, Nakamura S, Umemura T, Jitsuiki D, Soga J, et al. Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertens Res. 2007;30(9):775-80.

21. Conde DM, Verdade RC, Valadares ALR, Mella LFB, Pedro AO, Costa-Paiva L. Menopause and cognitive impairment: A narrative review of current knowledge. World J Psychiatry. 2021;11(8):412-28.

22. Hosoi M, Belcaro G, Saggino A, Luzzi R, Dugall M, Feragalli B. Pycnogenol(R) supplementation in minimal cognitive dysfunction. J Neurosurg Sci. 2018;62(3):279-84.

23. Cesarone MR, Belcaro G, Hosoi M, Ledda A, Feragalli B, Maione C, et al. Supplementary management with Pycnogenol® in Parkinson’s disease to prevent cognitive impairment. J Neurosurg Sci. 2020;64(3):258-62.

24. Belcaro G DM, Ippolito E, Hu S, Saggino A, Feragalli B Improvement in cognitive function, attention, mental performance with Pycnogenol® in healthy subjects (55-70) with high oxidative stress. J Neurosurg Sci 2015;59:437-46.

25. Ryan J, Croft, K., Wesnes, K and Stough, C. An examination of the effects of the antioxidant Pycnogenol® on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. J Psychopharmacol. 2008;22(5):553-62.

26. Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin North Am. 2013;39(1):1-19.

27. Jessberger S, Högger P, Genest F, Salter DM, Seefried L. Cellular pharmacodynamic effects of Pycnogenol(R) in patients with severe osteoarthritis: a randomized controlled pilot study. BMC Complement Altern Med. 2017;17(1):537.

28. Canali R, Comitato R, Schonlau F, Virgili F. The anti-inflammatory pharmacology of Pycnogenol in humans involves COX-2 and 5-LOX mRNA expression in leukocytes. Int Immunopharmacol. 2009;9(10):1145-9.

29. Grimm T, Chovanova Z, Muchova J, Sumegova K, Liptakova A, Durackova Z, et al. Inhibition of NF-kappaB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflamm (Lond). 2006;3:1.

30. Grimm T, Schäfer A, Högger P. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). Free Radic Biol Med. 2004;36(6):811-22.

31. Schäfer A, Chovanova Z, Muchova J, Sumegova K, Liptakova A, Durackova Z, et al. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother. 2005;60(1):5-9.

32. Belcaro G, Cesarone MR, Errichi S, Zulli C, Errichi BM, Vinciguerra G, et al. Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol. Redox Rep. 2008;13(6):271-6.

33. Farid R, Mirfeizi Z, Mirheidari M, Rezaieyazdi Z, Mansouri H, Esmaelli H, et al. Pycnogenol supplementation reduces pain and stiffness and improves physical function in adults with knee osteoarthritis. Nutrition Research. 2007;27(11):692-7.

34. Cisar P, Jany R, Waczulikova I, Sumegova K, Muchova J, Vojtassak J, et al. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytother Res. 2008;22(8):1087-92.

35. Belcaro G, Cesarone MR, Errichi S, Zulli C, Errichi BM, Vinciguerra G, et al. Treatment of osteoarthritis with Pycnogenol. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytother Res. 2008;22(4):518-23.

36. Mülek M, Seefried L, Genest F, Högger P. Distribution of Constituents and Metabolites of Maritime Pine Bark Extract (Pycnogenol((R))) into Serum, Blood Cells, and Synovial Fluid of Patients with Severe Osteoarthritis: A Randomized Controlled Trial. Nutrients. 2017;9(5).

37. Zhao H, Wu J, Wang N, Grether-Beck S, Krutmann J, Wei L. Oral Pycnogenol(R) Intake Benefits the Skin in Urban Chinese Outdoor Workers: A Randomized, Placebo-Controlled, Double-Blind, and Crossover Intervention Study. Skin Pharmacol Physiol. 2021:1-11.

38. Marini A, Grether-Beck S, Jaenicke T, Weber M, Burki C, Formann P, et al. Pycnogenol(R) effects on skin elasticity and hydration coincide with increased gene expressions of collagen type I and hyaluronic acid synthase in women. Skin Pharmacol Physiol. 2012;25(2):86-92.

39. Belcaro G, Cesarone MR, Errichi BM, Ledda A, Di Renzo A, Stuard S, et al. Diabetic ulcers: microcirculatory improvement and faster healing with pycnogenol. Clin Appl Thromb Hemost. 2006;12(3):318-23.

40. Ayres EL, Silva JDS, Eberlin S, Facchini G, Vasconcellos C, Costa A. In-vitro effect of pine bark extract on melanin synthesis, tyrosinase activity, production of endothelin-1 and PPAR in cultured melanocytes exposed to Ultraviolet, Infrared, and Visible light radiation. J Cosmet Dermatol. 2021.

41. Grether-Beck S, Marini A, Jaenicke T, Krutmann J. French Maritime Pine Bark Extract (Pycnogenol(R)) Effects on Human Skin: Clinical and Molecular Evidence. Skin Pharmacol Physiol. 2016;29(1):13-7.

42. Pinto CAS, Delfes MFZ, Reis LMd, Garbers LE, Passos PCVdR, Torre DSd. The use of pycnogenol in the treatment of melasma. Surgical & Cosmetic Dermatology. 2015;7(3).

43. Ni Z, Mu Y, Gulati O. Treatment of melasma with Pycnogenol. Phytother Res. 2002;16(6):567-71.

44. Saliou C, Rimbach G, Moini H, McLaughlin L, Hosseini S, Lee J, et al. Solar ultraviolet-induced erythema in human skin and nuclear factor-kappa-B-dependent gene expression in keratinocytes are modulated by a French maritime pine bark extract. Free Radic Biol Med. 2001;30(2):154-60.

45. Kim YJ, Kang KS, Yokozawa T. The anti-melanogenic effect of pycnogenol by its anti-oxidative actions. Food Chem Toxicol. 2008;46(7):2466-71.

46. Kwon SH, Na JI, Choi JY, Park KC. Melasma: Updates and perspectives. Experimental Dermatology. 2019;28(6):704-8.

47. Zouboulis CC, Blume-Peytavi U, Kosmadaki M, Roó E, Vexiau-Robert D, Kerob D, et al. Skin, hair and beyond: the impact of menopause. Climacteric. 2022;25(5):434-42.

48. Chaikittisilpa S, Rattanasirisin N, Panchaprateep R, Orprayoon N, Phutrakul P, Suwan A, et al. Prevalence of female pattern hair loss in postmenopausal women: a cross-sectional study. Menopause. 2022;29(4):415-20.

49. Cai C, Zeng B, Lin L, Zheng M, Burki C, Grether‐Beck S, et al. An oral French maritime pine bark extract improves hair density in menopausal women: A randomized, placebo‐controlled, double blind intervention study. Health Science Reports. 2023;6(1).

50. Cesarone MR, Belcaro G, Agus GB, Ippolito E, Dugall M, Hosoi M, et al. Chronic venous insufficiency and venous microangiopathy: management with compression and Pycnogenol(R). Minerva Cardioangiol. 2019;67(4):280-7.

51. Steigerwalt R, Belcaro G, Cesarone MR, Di Renzo A, Grossi MG, Ricci A, et al. Pycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy. J Ocul Pharmacol Ther. 2009;25(6):537-40.

52. Wang S, Tan D,  Zhao Y,  Gao G, Gao X, Hu L. The effect of Pycnogenol® on the microcirculation, platelet function and ischaemic myocardium in patients with coronary artery diseases. European Bulletin of Drug Research. 1999;7(2):19-25.

53. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G, et al. Improvement of diabetic microangiopathy with pycnogenol: A prospective, controlled study. Angiology. 2006;57(4):431-6.

54. Luzzi R BG, Hu S, Dugall M, Hosoi M, Cacchio M, Ippolito E, Corsi M Improvement in symptoms and cochlear flow with Pycnogenol in patients with Meniere’s disease and tinnitus. Minerva Med 2014;105:245-54.

55. Grossi MG, Belcaro G., Cesarone, M.R., Duggall, M., Hosoi, M Cacchio,. Improvement in cochlear flow with Pycnogenol® in patients with tinnitus: a pilot evaluation. Panminerva Med. 2010;52(2):63-7.

56. Chovanova Z, Muchova J, Sivonova M, Dvorakova M, Zitnanova I, Waczulikova I, et al. Effect of polyphenolic extract, Pycnogenol, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder. Free Radic Res. 2006;40(9):1003-10.

57. D̆uračková Z, Trebatický B, Novotný V, Žitňanová I, Breza J. Lipid metabolism and erectile function improvement by pycnogenol®, extract from the bark of pinus pinaster in patients suffering from erectile dysfunction-a pilot study. Nutrition Research. 2003;23(9):1189-98.

58. Devaraj S V-LS, Kaul N, Schönlau F, Rohdewald P, Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters plasma lipoprotein profile. Lipids. 2002;37(10):931-4.

59. Kolacek M, Muchova J, Dvorakova M, Paduchova Z, Zitnanova I, Cierna I, et al. Effect of natural polyphenols (Pycnogenol) on oxidative stress markers in children suffering from Crohn’s disease–a pilot study. Free Radic Res. 2013;47(8):624-34.

60. Errichi S, Bottari, A., Belcaro, G., Cesarone, M.R., Hosoi, M., Cornelli, U., Dugall, M., Ledda, A., Feragalli, B. Supplementation with Pycnogenol® improves signs and symptoms of menopausal transition. Panminerva Med. 2011;53(3):65-70.

61. Al-Badr A, Al-Shaikh G. Recurrent Urinary Tract Infections Management in Women: A review. Sultan Qaboos Univ Med J. 2013;13(3):359-67.

62. Lüthje P, Brauner H, Ramos NL, Ovregaard A, Gläser R, Hirschberg AL, et al. Estrogen supports urothelial defense mechanisms. Sci Transl Med. 2013;5(190):190ra80.

63. Cotellese R, Hu S, Cesarone MR, Belcaro G, Dugall M, Feragalli B, et al. Pycnogenol® supplementation prevents inflammation and symptoms in recurrent, non-severe urinary infections. Panminerva Med. 2021;63(3):343-8.

64. Ledda A, Hu S, Cesarone MR, Belcaro G, Dugall M, Feragalli B, et al. Pycnogenol® Supplementation Prevents Recurrent Urinary Tract Infections/Inflammation and Interstitial Cystitis. Evidence-Based Complementary and Alternative Medicine. 2021;2021:9976299.

World Menopause Month: Celebrate progress, power, and evidence

By
IHR Magazine
-
0

What we’re celebrating

Every October, World Menopause Month shines a positive spotlight on the menopause transition. It champions informed choice, equitable care, and supportive workplaces—culminating in World Menopause Day on 18 October. It’s a month to celebrate voice, science, and the everyday resilience of people navigating perimenopause and menopause.

How it began

World Menopause Day was launched by leading menopause specialists in 2009 to focus attention on quality of life in midlife health. By 2014, the effort expanded into a month-long, annual celebration so advocacy, education, and policy action could build momentum all October long.

The goal—now and next

  • Celebrate evidence-based care and informed decisions
  • Spark open conversations at home, in clinics, and across workplaces
  • Accelerate equitable access to treatment and trusted information
  • Recognize lived experience and reduce stigma through storytelling

What it looks like in practice

Clinics host Q&As, employers roll out supportive policies, media highlight real stories, and health bodies release refreshed guidance. The result is a growing culture of understanding—where people feel seen, supported, and set up to thrive.

Five standout wins in the last five years (2021–2025)

  1. Breakthrough non-hormonal relief
    Approval of a first-in-class NK3-R antagonist for moderate to severe hot flushes gave people who can’t—or prefer not to—use hormones a new, effective option.
  2. Clearer guidance on non-hormonal care
    Major societies published updated, practical roadmaps summarising which non-hormonal treatments work, for whom, and how to use them alongside lifestyle strategies.
  3. Workplace standards go mainstream
    A formal standard for menstruation and menopause support gave HR teams a blueprint to create inclusive policies, training, and adjustments.
  4. Legal clarity for employers
    Regulators issued guidance confirming duties to make reasonable adjustments where symptoms substantially affect day-to-day activities—prompting tangible change at work.
  5. Government-level women’s health strategies
    National strategies placed menopause squarely in long-term plans—improving information, services, and data so better care becomes the norm, not the exception.

The landmark shift since the early years

Perhaps the most significant arc of progress is the modern, evidence-based framing of menopausal hormone therapy (MHT/HRT). For most healthy people under 60—or within 10 years of menopause—the benefit–risk profile is favourable for troublesome vasomotor symptoms and bone protection. Today’s conversation is balanced, personalized, and centred on informed choice.

Celebrate with action

Host a lunch-and-learn. Review benefits and policies. Share patient stories. Bring in a menopause-informed clinician. Small actions add up—and October is the perfect time to make them stick.

Khloud Appoints Jeff Rubenstein as CEO to Spearhead Retail and Product Expansion

By
IHR Magazine
-
0

Los Angeles, CA — September 17, 2025 — Khloud, the rapidly growing protein snack startup founded by Khloé Kardashian, has announced a major leadership hire: Jeff Rubenstein has been appointed Chief Executive Officer. This move comes as Khloud prepares for its next phase of expansion, including launches this fall at Walmart, Kroger, Albertsons, and Ahold.

From Poppi to Khloud: Rubenstein Brings Deep Growth Experience

Rubenstein enters Khloud from his role as President and Chief Growth Officer at Poppi, where he helped scale brand awareness and sales. His background also includes positions at influential consumer brands such as Vita Coco, Health-Ade, and earlier work in brand management at The Coca-Cola Company.

At Khloud, his mandate involves accelerating expansion into major retailers, broadening the product portfolio, and building the brand’s cultural relevance among snack consumers. “Khloud has already proven it can capture attention in a crowded category,” said Khloé Kardashian in the official release. “Jeff understands how to take that momentum and turn it into long‐term growth.”

Operational Strength: New Supply Chain Leadership

To support the scaling efforts, Khloud has also appointed Michael Maya as Chief Supply Chain Officer. Maya will lead manufacturing and supply chain systems, ensuring that Khloud can meet demand with consistency in both quality and supply. Rubenstein emphasised that as distribution expands, strong supply chain and operations are critical.

Retail Expansion and Early Momentum

Khloud officially launched direct-to-consumer and began nationwide distribution via Target earlier this year. Since then, the brand’s protein popcorn offering has seen strong performance in the salty snack category.

This autumn’s launches at Walmart, Kroger, Albertsons, and various Ahold banners mark a crucial opportunity for Khloud to scale its physical retail footprint. For many startup food brands, moving from niche and online channels into big-box and supermarket grocers is a turning point. Under Rubenstein’s leadership, retail expansion is clearly central.

What This Means in the Broader Snack and Better-for-You Landscape

Demand for functional, cleaner snacks remains strong. Rubenstein has highlighted that consumers want snacks that deliver both taste and health benefits. Khloud is well positioned at that intersection.

Strategic leadership hires are another key factor. Jeff Rubenstein’s experience scaling brands, together with Michael Maya’s supply chain expertise, suggests Khloud is preparing for rapid growth—not just in sales, but in distribution efficiency and operational resilience.

Competitive category dynamics also play a role. The snack space is crowded, especially in better-for-you and functional snacks. Brands that succeed often combine product innovation, strong branding, and excellent execution in retail. Khloud’s early traction and upcoming large-scale roll-outs position it well.

Challenges and Considerations

Maintaining product quality and supply consistency will be essential as Khloud enters thousands of new stores. Brand differentiation will need to continue through packaging, flavour innovation, nutrition claims, and competitive positioning. Marketing and consumer engagement, especially with younger snackers, will require balancing authenticity and scale.

Looking Ahead

Under Rubenstein’s leadership, Khloud aims to convert its early momentum into long-term growth. The emphasis will likely be on strengthening retail presence across regional and national chains, expanding the product line beyond protein popcorn into other formats or flavours, scaling operations through robust supply chain and manufacturing systems, and deepening brand connection with target consumers who want clean, functional, and tasty options.

For Khloé Kardashian’s team, this milestone signals that Khloud isn’t just a celebrity-backed startup, but a serious contender in the snack food and better-for-you space. The next few quarters will be telling as the company translates its operational infrastructure, leadership hires, and retail placements into sustainable market share and consumer loyalty.

IHR Plugin: The Game-Changer for Natural Health Food Retail

By
IHR Magazine
-
0

Why This Will Transform Natural Health Food Retail

Natural health food retail faces unique pressures: consumers expect same-day or next-day delivery, but most small and mid-size shops can’t stock hundreds of SKUs or pay for large warehouses. The IHR Plugin changes the equation by letting any store—without coding—connect to a decentralized network of inventory and dropshipping, while automating marketing through built-in AI.

Decentralized Fulfillment and Lower Costs
Every participating retailer becomes a micro-warehouse. Orders placed online are routed to the closest store or vendor, resulting in reduced shipping times and lower freight costs. Retailers can show an “infinite shelf” of products without holding the inventory themselves.

AI Marketing Automation
The plugin’s AI instantly creates product descriptions, social posts, and email campaigns. Promotions can go live on Facebook, Instagram, TikTok, or Google Ads in one click, saving weeks of creative work and ensuring every product is marketed with SEO-ready content.

Control for Brands and Stores
Suppliers can set minimum advertised prices and control which retailers sell their goods, ensuring brand integrity and consistent pricing. Retailers gain a wider catalogue and rapid fulfilment without risking excess stock.

Simple and Affordable
Free to install and running within minutes, the IHR Plugin offers subscription plans from $99 to $2,999 per month, with transaction fees of only 2–5%. A unified dashboard provides full visibility of margins and performance.

By adopting this technology, natural health food stores can compete with major e-commerce platforms and meet the growing demand for fast and reliable delivery. The IHR Plugin’s Winter 2025/2026 launch will mark a new era in the health food retail industry.

1...8910...391Page 9 of 391

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

© 2026 IHR Magazine | Canada's Natural Health Industry Authority | Le guide de l’industrie canadienne de la santé naturelle